Dynamic Advisor Solutions LLC Purchases 1,377 Shares of Enovis Co. (NYSE:ENOV)

Dynamic Advisor Solutions LLC lifted its position in Enovis Co. (NYSE:ENOV) by 7.8% during the 4th quarter, HoldingsChannel reports. The firm owned 18,999 shares of the company’s stock after buying an additional 1,377 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Enovis were worth $834,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. UMB Bank n.a. increased its stake in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. raised its stake in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after purchasing an additional 300 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Enovis during the third quarter valued at approximately $55,000. FMR LLC grew its stake in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP bought a new position in shares of Enovis in the 3rd quarter worth $206,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

ENOV has been the subject of several research reports. Evercore ISI cut their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research report on Tuesday, October 1st. JMP Securities began coverage on Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.86.

Enovis Stock Up 1.1 %

ENOV opened at $47.78 on Monday. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The business’s 50-day moving average price is $45.93 and its 200-day moving average price is $44.46. The company has a market cap of $2.67 billion, a P/E ratio of -21.82 and a beta of 1.94.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. On average, equities analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.